Francesca Moretti
Novartis
19 Papers
229 Citations
Francesca Moretti is an academic researcher from Novartis. The author has contributed to research in topics: Biology & CRISPR. The author has an hindex of 13, co-authored 18 publications. Previous affiliations of Francesca Moretti include University of Basel.
Chat about Author
Papers
Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients
Luca Quagliata,Matthias S. Matter,Salvatore Piscuoglio,Salvatore Piscuoglio,Leila Arabi,Christian Ruiz,Alfredo Procino,Michal Kovac,Francesca Moretti,Zuzanna Makowska,Tujana Boldanova,Jesper B. Andersen,Monika Hämmerle,Luigi Tornillo,Markus H. Heim,Sven Diederichs,Clemente Cillo,Luigi Terracciano +17 more
TL;DR: It is demonstrated that the levels of HOTTIP and HOXA13 are associated with HCC patients' clinical progression and predict disease outcome, and novel insights on the function of lncRNA‐driven hepatocarcinogenesis are provided.
446
Mechanism of translational regulation by miR-2 from sites in the 5′ untranslated region or the open reading frame
TL;DR: This work shows that specific translational regulation is elicited in vitro and in vivo not only from the 3'UTR, but equally effectively from six Drosophila miR-2-binding sites in the 5' UTR or the ORF.
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.
Tia A. Tummino,Veronica V. Rezelj,Benoit Fischer,Audrey Fischer,Matthew J. O’Meara,Blandine Monel,Thomas Vallet,Kris M. White,Ziyang Zhang,Assaf Alon,Heiko Schadt,Henry R. O’Donnell,Jiankun Lyu,Romel Rosales,Briana L. McGovern,Raveen Rathnasinghe,Sonia Jangra,Michael Schotsaert,Jean-Rene Galarneau,Nevan J. Krogan,Laszlo Urban,Kevan M. Shokat,Andrew C. Kruse,Adolfo García-Sastre,Olivier Schwartz,Francesca Moretti,Marco Vignuzzi,Francois Pognan,Brian K. Shoichet +28 more
TL;DR: For example, this paper found that phospholipidosis was a shared mechanism underlying the antiviral activity of many repurposed drugs, including hydroxychloroquine, azithromycin, amiodarone, and four others already in clinical trials.
178
Functional CRISPR screening identifies the ufmylation pathway as a regulator of SQSTM1/p62
Rowena DeJesus,Francesca Moretti,Gregory McAllister,Zuncai Wang,Phil Bergman,Shanming Liu,Elizabeth Frias,John Alford,John S. Reece-Hoyes,Alicia Lindeman,Jennifer Kelliher,Carsten Russ,Judith Knehr,Walter Carbone,Martin Beibel,Guglielmo Roma,Aylwin Ng,John A. Tallarico,Jeffery A. Porter,Ramnik J. Xavier,Craig Mickanin,Leon Murphy,Gregory R. Hoffman,Beat Nyfeler +23 more
TL;DR: In this article, a forward genetic screening paradigm exploiting CRISPR-mediated genome editing coupled with a cell selection step by FACS was described to identify regulators of SQSTM1.
Genome-wide CRISPR screen for PARKIN regulators reveals transcriptional repression as a determinant of mitophagy
Christoph Potting,Christophe Crochemore,Francesca Moretti,Florian Nigsch,Isabel Schmidt,Carole Manneville,Walter Carbone,Judith Knehr,Rowena DeJesus,Alicia Lindeman,Rob Maher,Carsten Russ,Gregory McAllister,John S. Reece-Hoyes,Gregory R. Hoffman,Guglielmo Roma,Matthias Müller,Andreas W. Sailer,Stephen B. Helliwell +18 more
TL;DR: The critical role of PARKIN abundance is demonstrated, the identified genes negatively regulate PARKIN gene expression are identified, and a link between transcriptional repression and mitophagy is revealed, which is also apparent in human induced pluripotent stem cell-derived neurons, a disease-relevant cell type.
93